BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34538431)

  • 1. The Penetrance of Topical Nail Therapy: Limitations and Current Enhancements.
    Phan K; Kaur K; Wright K; Tran S; Stewart B; Brown M; Vlahovic TC
    Clin Podiatr Med Surg; 2021 Oct; 38(4):535-540. PubMed ID: 34538431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
    Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation of how fungal infection influences drug penetration through onychomycosis patient's nail plates.
    McAuley WJ; Jones SA; Traynor MJ; Guesné S; Murdan S; Brown MB
    Eur J Pharm Biopharm; 2016 May; 102():178-84. PubMed ID: 26969264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Presence of an Air Gap Between the Nail Plate and Nail Bed in Onychomycosis Patients: Treatment Implications for Topical Therapy.
    Gupta AK; Pillai R
    J Drugs Dermatol; 2015 Aug; 14(8):859-63. PubMed ID: 26267730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efinaconazole topical solution, 10%: formulation development program of a new topical treatment of toenail onychomycosis.
    Bhatt V; Pillai R
    J Pharm Sci; 2015 Jul; 104(7):2177-82. PubMed ID: 25940933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective.
    Elsayed MM
    J Control Release; 2015 Feb; 199():132-44. PubMed ID: 25481439
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Kubota-Ishida N; Takei-Masuda N; Kaneda K; Nagira Y; Chikada T; Nomoto M; Tabata Y; Takahata S; Maebashi K; Hui X; Maibach HI
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for the enhancement of nail plate permeation of drugs to treat onychomycosis.
    Gupta AK; Polla Ravi S; Choi SY; Konda A; Cooper EA
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):243-255. PubMed ID: 36196052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routes of drug delivery into the nail apparatus: Implications for the efficacy of topical nail solutions in onychomycosis.
    Gupta AK; Simpson FC
    J Dermatolog Treat; 2016; 27(1):2-4. PubMed ID: 25983025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
    Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
    J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical application of acidified nitrite to the nail renders it antifungal and causes nitrosation of cysteine groups in the nail plate.
    Finnen MJ; Hennessy A; McLean S; Bisset Y; Mitchell R; Megson IL; Weller R
    Br J Dermatol; 2007 Sep; 157(3):494-500. PubMed ID: 17627796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tavaborole for the treatment of onychomycosis.
    Elewski BE; Tosti A
    Expert Opin Pharmacother; 2014 Jul; 15(10):1439-48. PubMed ID: 24856836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
    Endringer Pinto F; Bagger C; Kunze G; Joly-Tonetti N; Thénot JP; Osman-Ponchet H; Janfelt C
    Mycoses; 2020 Aug; 63(8):869-875. PubMed ID: 32406142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug delivery to the nail: therapeutic options and challenges for onychomycosis.
    Barot BS; Parejiya PB; Patel HK; Mehta DM; Shelat PK
    Crit Rev Ther Drug Carrier Syst; 2014; 31(6):459-94. PubMed ID: 25271773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis.
    Kawai M
    Med Mycol J; 2019; 60(3):71-74. PubMed ID: 31474693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety and tolerability of an optimized avulsion technique with onyster® (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized evaluator-blinded controlled study.
    Lahfa M; Bulai-Livideanu C; Baran R; Ortonne JP; Richert B; Tosti A; Piraccini BM; Szepietowski JC; Sibaud V; Coubetergues H; Voisard JJ; Paul C
    Dermatology; 2013; 226(1):5-12. PubMed ID: 23467055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach.
    Kircik LH
    J Drugs Dermatol; 2014 Dec; 13(12):1457-61. PubMed ID: 25607788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical and physical strategies in onychomycosis topical treatment: A review.
    Angelo T; Borgheti-Cardoso LN; Gelfuso GM; Taveira SF; Gratieri T
    Med Mycol; 2017 Jul; 55(5):461-475. PubMed ID: 27703019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onychomycosis: Current Understanding and Strategies for Enhancing Drug Delivery into Human Nail Tissue.
    Aslam R; Hussain T; Yousaf AM; Ghori MU; Khan IU; Rizvi SAA; Shahzad Y
    Curr Drug Res Rev; 2021; 13(1):25-35. PubMed ID: 32735534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress on the topical therapy of onychomycosis.
    Alley MR; Baker SJ; Beutner KR; Plattner J
    Expert Opin Investig Drugs; 2007 Feb; 16(2):157-67. PubMed ID: 17243936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.